Search results for "Viral"

showing 10 items of 2737 documents

Becton Dickinson Directigen EZ Flu A+B assay in the diagnosis of pandemic influenza A H1N1 2009 virus infection in adult patients

2011

To the editor: The recent emergence and spread of the pandemic influenza A H1N1 2009 virus demands the evaluation of rapid antigen assays for their ability to detect this novel subtype of influenza A virus. Data on the ability of BD Directigen EZ Flu A+B immunochromatographic (IC) assay (Beckton Dickinson and Company, Sparks, MD, USA) to detect the pandemic influenza A virus strain in fresh clinical samples have been recently published. 1 , 2 , 3 , 4 , 5 In these studies, the majority of specimens were collected from pediatric patients, and the sensitivities reported ranged from 46·8% to 76·6%. As viral shedding in the upper respiratory tract during influenza virus infection is of greater m…

Pulmonary and Respiratory Medicinemedicine.diagnostic_testEpidemiologybusiness.industryPublic Health Environmental and Occupational HealthBecton dickinsonmedicine.disease_causeVirologyVirusPre- and post-test probabilityInfectious DiseasesImmunoassayPandemicInfluenza A virusMedicineInfection controlViral sheddingbusinessInfluenza and Other Respiratory Viruses
researchProduct

Molecular surveillance of norovirus, 2005–16 : an epidemiological analysis of data collected from the NoroNet network

2018

BACKGROUND: The development of a vaccine for norovirus requires a detailed understanding of global genetic diversity of noroviruses. We analysed their epidemiology and diversity using surveillance data from the NoroNet network.METHODS: We included genetic sequences of norovirus specimens obtained from outbreak investigations and sporadic gastroenteritis cases between 2005 and 2016 in Europe, Asia, Oceania, and Africa. We genotyped norovirus sequences and analysed sequences that overlapped at open reading frame (ORF) 1 and ORF2. Additionally, we assessed the sampling date and country of origin of the first reported sequence to assess when and where novel drift variants originated.FINDINGS: W…

0301 basic medicineDatabases FactualvirusesVARIANTSmedicine.disease_causeDisease OutbreaksEMERGENCEfluids and secretions[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesEpidemiologyGenotypeTOOLmedia_commonCaliciviridae InfectionsMolecular Epidemiologyvirus diseasesrespiratory system3. Good healthGastroenteritis[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInfectious DiseasesGeography[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyRNA Viral[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyOUTBREAKSmedicine.medical_specialtyEUROPEGenotypeTRANSMISSIONVIRUSES[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/Virology03 medical and health sciencesSDG 3 - Good Health and Well-beingGenetic driftEnvironmental healthmedicinemedia_common.cataloged_instanceHumansEuropean unionRetrospective StudiesGenetic diversityMolecular epidemiologyNorovirusOutbreakGenetic Variation[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyADULTSdigestive system diseasesEVOLUTION030104 developmental biology3121 General medicine internal medicine and other clinical medicineNorovirushuman activities
researchProduct

HEPATITIS C AND DIABETES: THE INEVITABLE COINCIDENCE?

2009

Type 2 diabetes (T2D) and HCV infection are common conditions involving, respectively, at least 170 and 130 million people worldwide. However, the distribution of such cases does not overlap in the same age groups in different geographic areas. Following pioneering reports of increased prevalence of T2D in HCV-positive cirrhosis, interest concerning the relationship between HCV and T2D has escalated. HCV is able to induce insulin resistance (IR) directly and the role of specific viral genotypes responsible for such effect is disputed. IR has consistently been found to be closely linked to fibrosis in HCV infection, although also typically associated with T2D in prefibrotic stages. HCV infec…

Liver CirrhosisMicrobiology (medical)medicine.medical_specialtyCirrhosisHepatitis C virusPopulationHepacivirusType 2 diabetesGlobal Healthmedicine.disease_causeMicrobiologyGastroenterologyRisk FactorsVirologyInternal medicineDiabetes mellitusPrevalencemedicineHumanseducationfatty livereducation.field_of_studydiabetesbusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis C; diabetes; fatty liverHepatitis Cdigestive system diseasesDIABETES HEPATITIS C INSULIN RESISTANCEInfectious DiseasesDiabetes Mellitus Type 2Hepatocellular carcinomaImmunologyInsulin ResistancebusinessViral hepatitis
researchProduct

Treatment options in HBV.

2005

The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to conclude that in patients with HBeAg positive chronic hepatitis, standard IFN therapy significantly improves clearance of HBeAg (number needed to treat [NNT] = 4), loss of HBV-DNA (NNT = 4) and clearance of HBsAg (NNT = 18). HBeAg positive patients with normal or slightly raised ALT should be treated only if there is histological evidence of progressive disease. In patients with HBeAg negative chronic hepatitis, less than 20% of subjects who have achieved an end-of-treatment virological response after a course of standard IFN maintain a sustained virological response in the long-term. IFN tre…

Hepatitis B virusHBsAgmedicine.medical_specialtyAdefovirmedicine.disease_causeAntiviral AgentsGastroenterologyHepatitis B AntigensLiver diseaseInternal medicineAdefovirHumansMedicineHepatitis B virusHepatologybusiness.industryvirus diseasesLamivudineHIVHepatitis Bmedicine.diseaseHepatitis Bdigestive system diseasesTreatmentTreatment OutcomeHBeAgLamivudineDNA ViralImmunologyNumber needed to treatInterferonbusinessLiver diseasemedicine.drug
researchProduct

SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients

2020

Background The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. Patients and methods This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers wer…

0301 basic medicineMaleAntibodies ViralSeverity of Illness IndexGastroenterologylaw.invention0302 clinical medicinelaw030212 general & internal medicinebiologyInflammatory biomarkersMiddle AgedIntensive care unitHospitalizationTiterInfectious DiseasesSpike Glycoprotein CoronavirusFemaleAntibodyCoronavirus InfectionsAdultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyPneumonia ViralNeutralizing antibodiesArticleVirus03 medical and health sciencesBetacoronavirusYoung AdultVirologyInternal medicineSeverity of illnessmedicineHumansPandemicsAgedRetrospective StudiesInflammationbusiness.industrySARS-CoV-2C-reactive proteinCOVID-19Retrospective cohort studyAntibodies NeutralizingFerritinbiology.proteinBinding Sites AntibodybusinessBiomarkers
researchProduct

Determination of enrichment factors for modified RNA in MeRIP experiments

2019

In the growing field of RNA modification, precipitation techniques using antibodies play an important role. However, little is known about their specificities and protocols are missing to assess their effectiveness. Here we present a method to assess enrichment factors after MeRIP-type pulldown experiments, here exemplified with a commercial antibody against N6-methyladenosine (m6A). Testing different pulldown and elution conditions, we measure enrichment factors of 4-5 using m6A-containing mRNAs against an unmodified control of identical sequence. Both types of mRNA carry 32P labels at different nucleotides, allowing their relative quantification in a mixture after digestion to nucleotides…

Models MolecularAdenosineAbsolute quantificationMethylationProtein Structure SecondaryGeneral Biochemistry Genetics and Molecular BiologyViral Proteins03 medical and health sciencesAdenosine TriphosphateRNA modificationEscherichia coliHumansImmunoprecipitationProtein Interaction Domains and MotifsNucleotideRNA MessengerMolecular Biology030304 developmental biologychemistry.chemical_classification0303 health sciencesMessenger RNACell-Free SystemChemistryElution030302 biochemistry & molecular biologyRNADNA-Directed RNA PolymerasesBiochemistryImmunoglobulin GIsotope LabelingChromatography Thin LayerPhosphorus RadioisotopesProtein BindingMethods
researchProduct

Bioactive pyrrole-based compounds with target selectivity

2020

The discovery of novel synthetic compounds with drug-like properties is an ongoing challenge in medicinal chemistry. Natural products have inspired the synthesis of compounds for pharmaceutical application, most of which are based on N-heterocyclic motifs. Among these, the pyrrole ring is one of the most explored heterocycles in drug discovery programs for several therapeutic areas, confirmed by the high number of pyrrole-based drugs reaching the market. In the present review, we focused on pyrrole and its hetero-fused derivatives with anticancer, antimicrobial, and antiviral activities, reported in the literature between 2015 and 2019, for which a specific target was identified, being resp…

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antineoplastic AgentsReview ArticlePyrroleAntiviral Agentschemistry.chemical_compoundAnti-Infective AgentsDrug DiscoveryHumansPyrrolesMolecular Targeted TherapyAntiviralTargeted compoundsPyrrolePharmacologyDrug discoveryChemistryOrganic ChemistryCOVID-19Biological activityGeneral MedicineAntimicrobialSettore CHIM/08 - Chimica FarmaceuticaCombinatorial chemistryAnticancerDrug DesignAntimicrobialPharmacophoreSelectivityEuropean Journal of Medicinal Chemistry
researchProduct

Assessment of SARS-CoV-2 RNA shedding in semen of 36 males with symptomatic, asymptomatic, and convalescent infection during the first and second wav…

2022

: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor, angiotensin-converting enzyme 2 (ACE2), has been identified in the human testis, but the risk of transmission of SARS-CoV-2 through sexual intercourse still needs to be defined. The goal of our study was to determine if SARS-CoV-2 is detectable in the semen of patients suffering or recovering from coronavirus disease-19 (COVID-19), still testing positive at nasopharyngeal swabs but showing mild or no symptoms at the time of sampling. Detection of SARS-CoV-2 RNA in semen was performed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and nested PCR targeting open reading frame (ORF) 1ab. Medical …

coronaviruMaleItalySARS-CoV-2SemenUrologyCOVID-19HumansRNA ViralGeneral MedicinePandemicssexual transmissionAsian Journal of Andrology
researchProduct

Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group

2019

Abstract Hepatitis C virus (HCV) remains a significant public health problem and is one of the major causes of chronic liver disease worldwide. In recent years many new tools to facilitate widespread HCV screening and new therapeutic options with excellent efficacy and tolerability profiles and cost lowering policies have become available. To fully utilise these new tools, the link between local and specialist centres for the management of HCV infection must be reinforced. In order to GAIN further insight into these aspects, with a particular focus on the Italian scenario, a group of experts met to discuss relevant aspects and open issues on chronic HCV. As a summary of that meeting, the fo…

Liver Cirrhosismedicine.medical_specialtyHepatitis C virusHepacivirusChronic liver diseasemedicine.disease_causeAntiviral Agents03 medical and health sciences0302 clinical medicineLinkage to careHumansMass ScreeningMedicineEradication; Hepatitis C virus; Linkage to careIntensive care medicineSocieties MedicalEradicationHepatologybusiness.industryHepatitis C virusAdvanced cirrhosisPublic healthManaged Care ProgramsGastroenterologyvirus diseasesFocus Groupsmedicine.diseaseHepatitis CFocus groupdigestive system diseasesItalyTolerability030220 oncology & carcinogenesisHCV030211 gastroenterology & hepatologybusinessHepatitis C viruHealthcare providers
researchProduct

Positive Role of the MHC Class-I Antigen Presentation Regulator m04/gp34 of Murine Cytomegalovirus in Antiviral Protection by CD8 T Cells

2020

Murine cytomegalovirus (mCMV) codes for MHC class-I trafficking modulators m04/gp34, m06/gp48, and m152/gp40. By interacting with the MHC class-Iα chain, these proteins disconnect peptide-loaded MHC class-I (pMHC-I) complexes from the constitutive vesicular flow to the cell surface. Based on the assumption that all three inhibit antigen presentation, and thus the recognition of infected cells by CD8 T cells, they were referred to as “immunoevasins.” Improved antigen presentation mediated by m04 in the presence of m152 after infection with deletion mutant mCMV-Δm06W, compared to mCMV-Δm04m06 expressing only m152, led us to propose renaming these molecules “viral regulators of antigen present…

0301 basic medicineMicrobiology (medical)BAC mutagenesisMuromegalovirusAdoptive cell transfer030106 microbiologyImmunologyAntigen presentationMutantlcsh:QR1-502CD8 T cellsPeptide bindingCD8-Positive T-LymphocytesMajor histocompatibility complexAntiviral AgentsMicrobiologylcsh:MicrobiologyMiceViral Proteins03 medical and health sciencesCellular and Infection MicrobiologyMHC class IAnimalsCytotoxic T cellnext-generation sequencing (NGS)adoptive cell transferimmune evasionAntigen PresentationMembrane GlycoproteinsbiologyMHC class I antigenHistocompatibility Antigens Class IimmunoevasinBrief Research ReportCell biology030104 developmental biologyInfectious Diseasesbiology.proteinrecombinant virusFrontiers in Cellular and Infection Microbiology
researchProduct